[1]李 刚,陈紫凡△.左西孟旦治疗老年慢性心力衰竭患者临床疗效及对患者心功能、肾素-血管紧张素-醛固酮系统的影响[J].陕西医学杂志,2020,49(10):1321-1324.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.032]
　LI Gang,CHEN Zifan..Curative effect of levosimendan in treatment of elderly patients with chronic heart failure and its influence on cardiac function and renin-angiotensin-aldosterone system[J].,2020,49(10):1321-1324.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.032]
点击复制

左西孟旦治疗老年慢性心力衰竭患者临床疗效及对患者心功能、肾素-血管紧张素-醛固酮系统的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年10期
页码:
1321-1324
栏目:
药物与临床
出版日期:
2020-10-05

文章信息/Info

Title:
Curative effect of levosimendan in treatment of elderly patients with chronic heart failure and its influence on cardiac function and renin-angiotensin-aldosterone system
作者:
李 刚; 陈紫凡△
厦门大学附属第一医院(厦门 361003)
Author(s):
LI Gang; CHEN Zifan.
The First Affiliated Hospital of Xiamen University(Xiamen 361003)
关键词:
慢性心力衰竭;  左西孟旦;  超声心动图;  氨末端脑利钠肽前体;  肾素-血管紧张素-醛固酮系统
Keywords:
Chronic heart failure;  Levosimendan;  Echocardiogram;  N-terminal pro brain natriuretic peptide;  Renin-angiotensin-aldosterone system
分类号:
R541.61
DOI:
DOI:10.3969/j.issn.1000-7377.2020.10.032
文献标志码:
A
摘要:
目的:探讨左西孟旦(Levo)对老年慢性心力衰竭患者(CHF)的心功能及肾素-血管紧张素-醛固酮系统(RAAS)的影响。方法:选取98例老年CHF患者,利用简单随机抽样法分为观察组(n=49例)和对照组(n=49例),对照组采用常规治疗,观察组在对照组基础上加用Levo治疗,比较两组治疗效果以及治疗前后超声心动图参数、心肌损伤因子以及RAAS指标的变化。结果:观察组治疗总有效率为95.92%明显高于对照组的81.63%(P<0.05); 观察组治疗后超声心动图参数每搏输出量(SV)、左室射血分数(LVEF)大于对照组(P<0.05),左心室舒张期末内径(LVEDD)、左室收缩末期内径(LVESD)和心肌损伤因子血清肌钙蛋白I(cTnI)、心型脂肪酸结合蛋白(H-FABP)、氨末端脑利钠肽前体(NT-proBNP)以及RAAS指标血清肾素(PRA)、血管紧张素Ⅱ(AngⅡ)、醛固酮(ALD)小于对照组(P<0.05)。结论:Levo应用于老年CHF临床效果良好,可有效改善患者心功能以及RAAS指标。
Abstract:
Objective:To explore the effect of levosimendan(Levo)on cardiac function and renin-angiotensin-aldosterone system(RAAS)in elderly patients with chronic heart failure(CHF).Methods:A total of 98 elderly CHF patients were selected.According to simple random sampling method,they were divided into observation group(n=49)and control group(n=49).The control group was given routine treatment,while observation group was additionally given Levo.The curative effect,changes of echocardiogram(ECG)parameters,myocardial injury factors and RAAS indexes before and after treatment were compared between the two groups.Results:The total effective rate of observation group was significantly higher than that of control group(95.92% vs.81.63%,P<0.05).After treatment,stroke volume(SV)and left ventricular ejection fraction(LVEF)of observation group were greater than those of control group(P<0.05),while left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),myocardial injury factors [serum cardiac troponin I(cTnI),heart-type fatty acid binding protein(H-FABP),N-terminal pro brain natriuretic peptide(NT-proBNP)] and RAAS indexes [plasma renin activity(PRA),angiotensin Ⅱ(Ang Ⅱ),aldosterone(ALD)] were lower than those of control group(P<0.05).Conclusion:The clinical effect of Levo is good in the treatment of the elderly with CHF,which can effectively improve their cardiac function and RAAS indexes.

参考文献/References:

[1] Drozd M,Gierula J,Lowry JE,et al.Cardiac resynchronization therapy outcomes in patients with chronic heart failure:cardiac resynchronization therapy with pacemaker versus cardiac resynchronization therapy with defibrillator[J].Journal of Cardiovascular Medicine,2017,18(12):962-967.
[2] Billebeau G,Vodovar N,Sadoune M,et al.Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure[J].European Journal of Preventive Cardiology,2017,24(11):1127-1135.
[3] Zhao J.X indening oral liquid improves cardiac function of rats with chronic cardiac failure via TGF-β1/Smad3 and p38 MAPK pathway[J].Anatolian Journal of Cardiology,2017,17(5):367-373.
[4] 向宗兴,拓 文,仇卫峰,等.黄芪保心汤配合西药治疗慢性心力衰竭临床研究[J].陕西中医,2019,40(8):1085-1087.
[5] 陶 莉,赵晓茜,宋成运,等.左西孟旦治疗老年慢性心力衰竭急性发作的临床研究[J].中西医结合心脑血管病杂志,2019,17(17):2627-2630.
[6] 孙 飞,王海珠,刘丹丹,等.左西孟旦对老年急性心力衰竭患者心脏功能MACE事件及不良反应的影响[J].安徽医学,2019,40(6):621-624.
[7] 俞瑞群,王 丹,吴晓蓉,等.左西孟旦治疗老年慢性心力衰竭急性加重患者的临床疗效[J].实用心脑肺血管病杂志,2018,26(5):88-90.
[8] 张 健,邹长虹.《2016年欧洲心脏病学会急慢性心力衰竭诊断与治疗指南》非药物治疗部分解读[J].中国介入心脏病学杂志,2016,24(11):612-615.
[9] 林施峰,李世阁,林基表,等.左西孟旦对扩张型心肌病慢性心力衰竭患者心功能的影响及疗效观察[J].安徽医学,2018,39(11):1339-1343.
[10] Yamamoto H,Yamada T,Tamaki S,et al.Prediction of sudden cardiac death in patients with chronic heart failure by regional washout rate in cardiac MIBG SPECT imaging[J].Journal of Nuclear Cardiology,2017,26(1):109-117.
[11] Packer M.Major reduction in the risk of sudden cardiac death in patients with chronic heart failure with the use of drug and device combinations that favourably affect left ventricular structure[J].European Journal of Heart Failure,2019,21(7):823.
[12] 谭 涛,吴 曦.依那普利联合瑞舒伐他汀对慢性心衰患者血管内皮功能、氧自由基代谢以及血清炎性因子的影响[J].陕西医学杂志,2018,47(9):1192-1195.
[13] 姚宏英,杨胜利,杨 勇,等.超声心动图评价慢性心力衰竭患者右心室功能障碍及其与左心室射血分数的关系[J].中国临床医生杂志,2018,46(3):285-287.
[14] 杜 晶.慢性心力衰竭药物治疗新进展[J].微循环学杂志,2018,28(1):67-70.
[15] 张 亮,李海林.左西孟旦对顽固性心力衰竭患者心功能的影响[J].中国中西医结合急救杂志,2019,26(3):307-309.
[16] 周红瑜,厉旭光,颜碧清.左西孟旦对急性心力衰竭患者心功能和血流动力学及炎性因子的影响[J].中国医药,2018,13(11):1605-1608.
[17] 陈 桐,沈 敏.左西孟旦和米力农治疗对心力衰竭患者血管内皮因子、心室重构及心功能的影响[J].标记免疫分析与临床,2019,26(2):95-98,119.
[18] 吴林栩,王卿语,叶张章,等.常规治疗加用左西孟旦治疗慢性进展性心力衰竭的疗效[J].心脏杂志,2018,30(6):713-715.
[19] 周志祥,黄元飞.左西孟旦联合美托洛尔对老年慢性心力衰竭患者心功能、N端脑钠肽前体和心室重构的影响[J].药物评价研究,2019,42(6):1156-1159.
[20] 彭艳玲,王冉冉,黄 洁,等.左西孟旦治疗慢性心力衰竭的疗效分析[J].中国急救复苏与灾害医学杂志,2018,13(6):533-535.

相似文献/References:

[1]王 毅,杨 征.托伐普坦和沙库巴曲缬沙坦钠片对慢性心力衰竭患者心功能及血清钠水平的影响研究[J].陕西医学杂志,2019,(4):470.
[2]申文文,延欢欢.不同类型慢性心力衰竭患者血清肌钙蛋白T和N末端B型钠尿肽原水平变化及临床意义[J].陕西医学杂志,2021,50(9):1109.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.017]
　SHEN Wenwen,YAN Huanhuan.Changes and clinical significance of serum TnT and NT-proBNP levelsin patients with different types of CHF[J].,2021,50(10):1109.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.017]
[3]陈金权,王 蕊.右美托咪定对慢性心力衰竭大鼠的作用及机制研究[J].陕西医学杂志,2022,51(6):664.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.005]
　CHEN Jinquan,WANG Rui.Effect and mechanism of dexmedetomidine on chronic heart failure in rats[J].,2022,51(10):664.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.005]
[4]屈 慧,李 娅.肾功能及电解质水平变异性与慢性心力衰竭患者预后相关性研究[J].陕西医学杂志,2023,52(3):287.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.009]
　QU Hui,LI Ya.Correlation between variability of renal function and electrolyte levels and prognosis of patients with chronic heart failure[J].,2023,52(10):287.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.009]
[5]刘天牧,滕 玥.沉默信息调节因子1/叉头转录因子1通路上调微小RNA-203对慢性心力衰竭大鼠的干预实验研究[J].陕西医学杂志,2023,52(10):1289.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.002]
　LIU Tianmu,TENG Yue.Experimental study on intervention of silent information regulator 1/ forkhead transcription factor 1 pathway up-regulating microRNA-203 in rats with chronic heart failure[J].,2023,52(10):1289.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.002]
[6]梅丽军,姚 筱,王西强,等.左西孟旦联合辅酶Q10治疗扩张型心肌病临床疗效研究[J].陕西医学杂志,2023,52(10):1404.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.027]
　MEI Lijun,YAO Xiao,WANG Xiqiang,et al.Efficacy of levosimendan combined with coenzyme Q10 in patients with dilated cardiomyopathy[J].,2023,52(10):1404.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.027]
[7]张小用,肖仁喜,方 媛.左心室心肌收缩力在体计算方法及其临床应用价值[J].陕西医学杂志,2023,52(11):1526.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.016]
[8]王丽辉,徐 佳,姜 晶.沙库巴曲缬沙坦联合螺内酯治疗慢性射血分数降低的心力衰竭临床价值研究[J].陕西医学杂志,2024,(5):675.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.022]
　WANG Lihui,XU Jia,JIANG Jing.Value of sacubitril/valsartan combined with spironolactone in the treatment of chronic heart failure with reduced ejection fraction[J].,2024,(10):675.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.022]
[9]高泽林,李晓妮.新活素与左西孟旦治疗缺血性心肌病致心力衰竭疗效及对患者心功能指标的影响[J].陕西医学杂志,2024,(10):1394.[doi:DOI:10.3969/j.issn.1000-7377.2024.10.021]
[10]韩 萌,李玉洁,杨国宁,等.人参皂苷通过JAK激酶/信号转导和转录激活因子信号通路抑制慢性心衰大鼠心肌自噬的机制研究[J].陕西医学杂志,2025,54(1):33.[doi:DOI:10.3969/j.issn.1000-7377.2025.01.006]
　HAN Meng,LI Yujie,YANG Guoning,et al.The mechanism of ginsenosides inhibiting myocardial autophagy in chronic heart failure rats through JAK/STAT signaling pathway[J].,2025,54(10):33.[doi:DOI:10.3969/j.issn.1000-7377.2025.01.006]

更新日期/Last Update: 2020-10-10